Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
GENEVA, April 5, 2016 -- ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 9:00 a.m. ET at the Westin Grand Central Hotel in New York City.
About ObsEva
ObsEva is a biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is supported by For more information, please visit www.ObsEva.com.
CONTACT: MEDIA CONTACT
Gretchen Schweitzer or Blair Atkinson
MacDougall Biomedical Communications
Direct: +49 172 861 8540 or +1 812 454 6257
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
COMPANY CONTACT
Delphine Renaud
ObsEva CEO Office
+41 22 552 1550
[email protected]
IR CONTACT
Amy Conrad
Juniper Point
+1 858 914 1962
[email protected]
